文献速递免疫规划传染病防控与疫情报告

DNA疫苗与融合前F蛋白联合免疫保护雏鸡抵抗新城疫

Protection of chicks from Newcastle disease by combined vaccination with a plasmid DNA and the pre-fusion protein of the virulent genotype VII of Newcastle disease virus.
PubMed 文献 · Vaccine · 2020-09-25

研究构建了四种密码子优化的质粒DNA疫苗,表达中国分离的强毒基因VII型新城疫病毒F蛋白的融合前构象。其中pCAG-optiF-2质粒单独免疫提供部分临床保护,采用DNA初免+蛋白加强策略可诱导更强免疫应答,对强毒攻击提供完全临床保护、减少排毒并限制组织病毒复制。

要点

  • pCAG-optiF-2质粒单独免疫对雏鸡提供部分临床保护。
  • DNA初免+蛋白roptiF-2加强免疫诱导体液免疫优于单独免疫。
  • DNA初免+蛋白加强实现完全临床保护并减少排毒和组织病毒复制。

核心结论

  • F蛋白融合前构象可作为新型新城疫疫苗的靶免疫原。
  • DNA初免+蛋白加强策略对强毒NDV攻击提供更有效保护。

研究设计与样本

  • 构建四种密码子优化质粒(pCAG-optiF-1、2、-3、-4),含中国分离强毒基因VII型NDV的修饰F基因。
  • 在鸡源细胞中检测F变体表达,从悬浮细胞表达纯化两种可溶性F变体(roptiF-1和2)。
  • 以雏鸡为对象比较各质粒DNA疫苗单独免疫及pCAG-optiF-2初免+roptiF-2加强策略的免疫保护效果。

主要发现

  • 各质粒DNA疫苗单独免疫均对雏鸡提供部分临床保护。
  • pCAG-optiF-2编码切割位点突变、具融合前构象的可溶性蛋白,保护优于其他质粒。
  • ELISA和病毒中和试验显示DNA初免+蛋白加强抗体应答强于单独pCAG-optiF-2或roptiF-2。
  • DNA初免+蛋白加强对强毒NDV攻击提供完全临床保护、减少排毒并限制组织病毒复制。

临床怎么用

  • 提示DNA初免+蛋白加强策略可用于新城疫新型疫苗研发。
  • 融合前F蛋白构象是疫苗免疫原设计的重要考虑因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In this study, four codon optimized plasmids (designated as pCAG-optiF-1, 2, -3, and -4) containing modified F genes from the epidemic and virulent NDV genotype VII strain isolated in China that is expected to express the pre-fusion conformation of the F protein were constructed. The expression of these F variants in chicken-derived cells was detected by an indirect immunofluorescence assay and western blot analysis. Two soluble F variants (roptiF-1 and 2) potentially with the pre-fusion conformation were expressed and purified from suspended cells. Vaccination with each of the plasmids as a DNA vaccine conferred partial clinical protection to chicks against NDV. Comparatively, the plasmid pCAG-optiF-2 encoded a soluble protein with a mutant cleavage site and the potential pre-fusion conformation provided better protection than the other plasmids. Further investigation of the combined vaccinations with the plasmid DNA pCAG-optiF-2 prime + protein roptiF-2 boost vaccination strategy elicited more robust immunity, as confirmed by the detection of antibodies against NDV using enzyme-linked immunosorbent assay and virus neutralization assay, as compared to those vaccinated with only the plasmid pCAG-optiF-2 or protein roptiF-2. More importantly, the DNA prime + protein boost vaccination provided more efficacious protection against virulent NDV challenge, as evidenced by the complete clinical protection, reduced viral shedding, and limited virus replication in tissues of the challenge chicks. These results indicated that the pre-fusion conformation of the F protein could be considered as the target immunogen for the development of novel NDV vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sun J, Han Z, Zhao R, et al. Protection of chicks from Newcastle disease by combined vaccination with a plasmid DNA and the pre-fusion protein of the virulent genotype VII of Newcastle disease virus. Vaccine. 2020. PMID: 32981778. doi:10.1016/j.vaccine.2020.09.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。